Pharmaceutical Sciences Asia
Pharm Sci Asia 2020; 47 (1), 37-42
DOI:10.29090/psa.2020.01.019.0012
Research Article
Comparative in vitro activity of sitafloxacin against
multidrug-resistant and carbapenem-resistant
Acinetobacter baumannii clinical isolates in Thailand
Taniya Paiboonvong1,
Vipavee Rodjun2,
Jantana Houngsaitong1,
Mullika Chomnawang3,
Preecha Montakantikul2,
Suvatna Chulavatnatol2*
1
Department of Pharmacy, Faculty of Pharmacy,
Mahidol University, Bangkok, Thailand
2
Faculty of Pharmacy, Siam University, Bangkok,
Thailand
3
Department of Microbiology, Faculty of Pharmacy,
Mahidol University, Bangkok, Thailand
*Corresponding author:
suvatna.chu@mahidol.ac.th
KEYWORDS:
Sitafloxacin; Multidrug-resistant
A. baumannii; Carbapenem-resistant
A. baumannii
ABSTRACT
The rapid emergence of multidrug-resistant Acinetobacter
baumannii (MDRAB) is recognized as a significant health
problem worldwide, including Thailand. Due to a limitation of
treatment option, a new antimicrobial agent has been challenged.
Sitafloxacin, a new fluoroquinolone antimicrobial agent, has
shown a good in vitro activity against MDRAB and carbapenemresistant A. baumannii (CRAB). The aim of this study was to
evaluate in vitro activity of sitafloxacin and compare that with
other antimicrobial agents against A. baumannii clinical isolates,
focusing on multidrug-resistant A. baumannii and carbapenemresistant A. baumannii (MDR-CRAB). All 350 A. baumannii
clinical isolates were collected from thirteen tertiary care
hospitals in all regions of Thailand. The minimum inhibitory
concentrations (MICs) were determined by broth microdilution
method. To determine rate of susceptibilities, a susceptible
isolate with sitafloxacin was considered as MIC values of ≤
2 µg/mL and ≤ 1 µg/mL. For other antimicrobial agents, MIC
breakpoints were considered according to the Clinical and
Laboratory Standards Institute (CLSI) 2018. Our study found
that 278 clinical isolates were identified as MDR-CRAB. The
MIC range, MIC50 and MIC90 of sitafloxacin against MDRCRAB isolates were ≤ 0.0625-8 µg/mL, 1 µg/mL and 2 µg/
mL, respectively. Additionally, almost of the colistin-resistant
isolates were susceptible to sitafloxacin (92.86%). Sitafloxacin
had a good activity against multidrug-resistant isolates in
Thailand. Thus, sitafloxacin can be considered as an alternative
choice for treatment of MDRAB and CRAB infections. Further
studies are needed to evaluate treatment outcomes.
1. INTRODUCTION
https://www.pharmacy.mahidol.ac.th/journal/
© Faculty of Pharmacy, Mahidol University
(Thailand) 2020
Acinetobacter baumannii is an important cause of
nosocomial infections, and becomes a major problem in healthcare
settings in Asian countries, including Thailand. The resistance
to numerous different drug classes known as multidrug-resistant
A. baumannii (MDRAB) has rapidly emerged, and associated
with a high mortality rate, especially in critically ill patients1.
Carbapenems have been mainly used for treatment of MDRAB,
whereas the resistant rate has been rising over the world.
According to the National Antimicrobial Resistance Surveillance
T. Paiboonvong et al.
Thailand (NARST) data, carbapenem-resistant
A. baumannii (CRAB) has rapidly emerged for two
decades up to approximately 80% in 20162. Moreover,
several studies reported high rates of MDRAB and
CRAB from tertiary care hospitals in Thailand3,4.
Choosing the effective agent for treatment of
infections caused by those resistant pathogens is
challenging. The therapeutic option for MDRAB
and CRAB is mainly limited to colistin as the firstline treatment. However, the limitations of colistin are
the issue of renal toxicity and poor tissue penetration.
Therefore, new antimicrobial agents are needed
for treating resistant A. baumannii infections
Sitafloxacin (DU-6859a) is a new broadspectrum fluoroquinolone antimicrobial agent,
showed an active activity against many drug
resistant pathogens. Comparing with other fluoroquinolones, sitafloxacin has the lowest inhibitory concentration (IC50) against DNA gyrase and
topoisomerase IV5, 6. It has been approved for oral
formulation and used in Thailand for treatment of
urinary tract infections (UTIs) and lower respiratory
tract infections (LRIs) since 2011. Moreover, several
studies reported a potent activity of sitafloxacin
against drug-resistant A. baumannii7-12. Nevertheless,
the activity of sitafloxacin against both MDRAB
and CRAB (MDR-CRAB) isolates collected from
all regions of Thailand has not been reported.
Therefore, this study was conducted to provide an
informative data of sitafloxacin against A. baumannii
clinical isolates at tertiary hospitals in Thailand,
focusing on MDR-CRAB.
2. MATERIALS AND METHODS
2.1. Hospitals and bacterial isolates
All 350 A. baumannii clinical isolates
were collected from in-patients of thirteen tertiary
care hospitals, Thailand during the period of
2016. Non-duplicated isolates were collected. All
isolates were cultured in suitable media and storage
before sending to the laboratory of microbiology at
Faculty of Pharmacy, Mahidol University. Bacterial
glycerol stocks were prepared and stored at -80°C
until being tested.
2.2. Antimicrobial susceptibility tests
Broth microdilution method was used to
determine minimum inhibitory concentration (MIC)
38
Pharm Sci Asia 2020; 47 (1), 37-42
for sitafloxacin and comparators; ciprofloxacin,
ceftazidime, imipenem, meropenem, doripenem,
sulbactam, and colistin according to recommendation from CLSI 201613.
The standard powder of sitafloxacin was
provided by Daiichi Sankyo, Thailand. Standard
powders of ciprofloxacin, ceftazidime, colistin, and
sulbactam were purchased from Tokyo Chemical
Industry CO.,LTD. Standard powders of imipenem
and meropenem were purchased from Siam
Bheasach CO.,LTD, and doripenem was purchased
from Shinogal & CO.,LTD. The MIC values were
defined as the lowest concentration of an antimicrobial agent to inhibit a visible growth. The
MIC50 and the MIC90 were determined as a
concentration that inhibited 50% and 90% of isolates,
respectively. Since no MIC breakpoint of sitafloxacin
has been published by the CLSI, MIC breakpoint
≤ 2 µg/mL and ≤ 1 µg/mL were considered as
susceptible to sitafloxacin in previous studies7,8,12.
Other antimicrobial susceptibilities were interpreted
according to breakpoints criteria from CLSI 201814.
MDRAB and CRAB were identified by
the results of susceptibility by broth microdilution
method. MDRAB in this study was defined as
an isolate resistant to at least three antimicrobial
classes according to the interim standard definitions
for multidrug-resistant organism, which was created
by the European Centre for Disease Prevention
and Control and the Centers for Disease Control and
Prevention15. Escherichia coli ATCC 25922 was used
for quality control strain in this study. The bacterial
isolates were grown in Luria-Bertani broth (LB,
BD) and cation-adjusted Mueller-Hinton Broth
(CAMHB, BD) media. Serial two-fold dilutions of
antimicrobials tested for MIC were prepared in
CAMHB as described in CLSI guidelines. Bacterial
isolates were adjusted for a final inoculum density
approximately 5 × 105 CFU/mL using 0.5 McFarland
turbidity standard. All 96-well plates were incubated
at 37°C in ambient air for 20 hours. The method was
performed as the recommendations from CLSI
201613.
3. RESULTS AND DISCUSSION
Our study found that 278 clinical isolates
were MDR-CRAB. Most of the isolates were from
sputum (78.06%) followed by pus (8.99%), urine (5.40%),
blood (4.32%), tissue (2.16%), and nasophyrynx (0.72%).
Pharmaceutical Sciences Asia
Overall, sitafloxacin showed high rate of susceptibility than those of other comparative agents.
Sitafloxacin showed the best activity among
comparators against MDR-CRAB isolates when
using MIC breakpoint ≤ 2 µg/mL; the susceptibility
rate was 90.65%. Secondary to colistin, the susceptibility rate was 64.03% when MIC breakpoint ≤
1 µg/mL. The MIC range, MIC50 and MIC90 of
sitafloxacin were ≤ 0.0625-8 µg/mL, 1 µg/mL and
2 µg/mL, respectively. Additionally, 41 out of 278
isolates (14.75%) were resistant to colistin (MIC ≥
4 µg/mL), and almost of all isolates (92.86%) were
susceptible to sitafloxacin with MICs of ≤ 2 µg/mL
(MIC values ranged from < 0.0625-2 µg/mL).
We found the high MIC50 (2 µg/mL) and MIC90
(4 µg/mL) of sitafloxacin from isolates of the hospitals
in the central region. Antimicrobial susceptibility
results and MIC distribution of sitafloxacin
categorized by regions in Thailand are presented
in Table 1, and Table 2, respectively.
Table 1. The antimicrobial susceptibility and MIC values of 278 MDR-CRAB isolates
Antimicrobial
Susceptibility
breakpoints (μg/mL)
agents
Colistin
Sitafloxacin
Ciprofloxacin
Imipenem
Meropenem
Doripenem
Sulbactam
Ceftazidime
≤2
≤ 1, ≤ 2
≤1
≤2
≤2
≤2
≤4
≤8
MIC (µg/mL)
MIC50
MIC90
ranges
0.0625 - 512
≤ 0.0625 - 8
0.5 - > 512
8 - 256
8 - 256
2 - 256
2 - 2048
16 - > 512
0.5
1
64
32
32
16
16
512
Susceptibility %
4
2
> 512
128
64
64
128
> 512
85.25
64.03, 90.65
1.08
0
0
0.72
8.27
0
Table 2. The MIC distribution of sitafloxacin against MDR-CRAB isolates (n=278)
Hospital Regions
Central* (n=88)
North (n=66)
South (n=40)
East (n=23)
Northeast (n=61)
Total (278)
≤ 0.0625 0.25
2
2
2
0
0
6
3
0
0
2
2
7
0.5
MIC (µg/mL)
1
2
4
8
MIC50
MIC90
11
24
5
10
17
67
19
26
21
7
25
98
0
0
1
1
0
2
2
1
1
0.5
1
1
4
2
2
2
4
2
39
12
10
3
10
74
14
2
1
0
7
24
*
central region included Bangkok
Our results suggest that sitafloxacin has
a good activity against MDR-CRAB. The results
were consistent with previous studies that showed
a high susceptibility rate of sitafloxacin against
A. baumannii. The susceptibility rates of sitafloxacin
against A. baumannii isolated in 2016 and 2012
from Thai patients with UTIs and LRIs were 57.9%
and 87.9% and were 66.9% and 94.1% when MIC
breakpoint ≤ 1 µg/mL, and ≤ 2 µg/mL, respectively7,8.
This indicated that sitafloxacin remains active
against A. baumannii isolated from Thai patients
over the past 5 years. However, the MIC90 of
A. baumannii isolated in 2016 was 4 µg/mL, higher
than that in 2012 (the MIC90 was 2 µg/mL)7,8.
Similar to the study of Thamlikitkul and Tiengrim,
the susceptibility of CRAB to sitafloxacin was
91.4% when MIC breakpoint ≤ 2 µg/mL9. Another
report from Thailand showed a similar result that
39
T. Paiboonvong et al.
the susceptibility rate of sitafloxacin against
CRAB using disk diffusion method was 66.32% in
which the zone diameters for susceptibility referred
to the MIC breakpoint ≤ 1 µg/mL10. According to
Dong et al, the susceptibility rate of sitafloxacin
against 24 extensively drug-resistant (XDR)
A. baumannii isolates was 91.67% when MIC
breakpoint ≤ 2 µg/mL11. By contrast from Huang
et al, the susceptibility rate of sitafloxacin against
bacteremic isolates of CRAB was 58.9% that lower
than the rate of our study, and the MIC50 and
MIC90 were high as 2 µg/mL and 8 µg/mL,
respectively12. This may result from those isolates
were collected from only single center of teaching
hospital, but our study collected the isolates from
both teaching and provincial hospitals in all regions
of Thailand. Comparing to other agents, sitafloxacin
was more active than ceftazidime, ciprofloxacin,
and sulbactam in which the resistant rate was 100%,
98.92%, and 91.73%, respectively. Our results were
consistent with previous reports that overall
susceptibility rate of those agents was lower than
25%7,8,10,12.
Multiple acquired resistance determinants
have been found in MDRAB and CRAB, including
transfer of plasmids, transposons, and integrons,
encoding a resistant gene to several antimicrobial
classes. A mutation in quinolone resistance-determining region (QRDR) of target genes encoding
DNA gyrase (gyrA) and topoisomerase IV (parC)
has been reported as the main mechanism of
quinolone resistance in A. baumannii. In addition,
the plasmid-mediated quinolone resistance (PMQR)
genes have also been found and conferred high
level resistance to ciprofloxacin16,17. Our study found
that almost of all isolates were resistant to ciprofloxacin; MIC values ranged from 4 to > 512 µg/mL,
however, all of ciprofloxacin-resistant isolates were
susceptible to sitafloxacin. This advantage of
sitafloxacin may be a potent activity to inhibit the
target enzymes of Gram-negative pathogens; it
exhibited the lower IC50 than ciprofloxacin approximately 4-fold against the mutations in type II
topoisomerases of Pseudomonas aeruginosa6.
Colistin-resistant A. baumannii (CoR-AB)
has been reported from various countries over
the world, including Thailand18-23. Similar to our
study, CoR-AB isolates were found in 14.75%.
Interestingly, almost of all CoR-AB were susceptible
40
Pharm Sci Asia 2020; 47 (1), 37-42
to sitafloxacin (92.86%) probably involved the
difference of resistant mechanism. The main
mechanism of CoR-AB has been proposed as
alteration of lipopolysaccharide (LPS); lipid A
modification or loss of LPS19-21. Overexpression
of efflux pump system has been reported for the
mechanism of resistance, and recently found in
clinical isolates from Thailand22,23. However,
sitafloxacin resistance to A. baumannii has not
been reported as an overexpression by efflux
pump system. Although the mobile colistin resistance
gene mcr-1 has been found in gram negative
pathogens, especially E. coli, the mcr-1 has not yet
been reported on A. baumannii clinical isolates20.
However, mcr-1-carrying plasmid could be introduced
into A. baumannii, and co-localized with multiple
plasmid replicon types, which may be involved in
resistance to quinolones24,25. The limitation of this
study is that there is no standard MIC breakpoint
criteria for susceptibility established for sitafloxacin.
Although synergistic effects of sitafloxacin in
combination with colistin, sulbactam, rifampicin,
and tigycycline were reported against XDR-A.
baumannii11, combinations against MDRAB and
CRAB should be investigated to confirm a result
of different strains in Thailand.
4. CONCLUSION
Sitafloxacin showed a good in vitro activity
against MDR-CRAB, including colistin-resistant
isolates. Thus, sitafloxacin can be considered as
an alternative choice for treatment of infections
caused by resistant strains. Further studies are
needed to evaluate treatment outcomes.
5. ACKNOWLEDGEMENTS
We would like to thank Daiichi-Sankyo
(Thailand) Ltd. for providing sitafloxacin powder.
We also thank microbiology staffs from all
hospitals for specimrns collection; Taksin Hospital,
Klang Hospital, Nakhon Pathom Hospital, Samut
Sakhon Hospital, Maharaj Nakorn Chiang Mai
Hospital, Buddhachinaraj Hospital, Sawanpracharak
Hospital, Surat Thani Hospital, Maharaj Nakhon
Si Thammarat Hospital. Chonburi Hospital,
Sunpasitthiprasong Hospital, Surin Hospital, and
Buriram Hospital.
Pharmaceutical Sciences Asia
Conflict of interests
The authors declare no conflicts of interests in
this research.
Funding
No funding to declare
7.
Ethical approval
The study protocol was approved by the Institutional
Review Board of the Faculty of Dentistry and
Faculty of Pharmacy, Mahidol University (MUDT/PY-IRB 2017/040.2607).
8.
Article info:
Received February 6, 2019
Received in revised form March 25, 2019
Accepted April 19, 2019
REFERENCES
1. Chung DR, Song JH, Kim SH, Thamlikitkul V,
Huang SG, Wang H, et al. High prevalence of
multidrug-resistant nonfermenters in hospitalacquired pneumonia in Asia. Am J Respir Crit
Care Med. 2011;184(12):1409-17.
2. National Antimicrobial Resistance Surveillance
Center (NARST). Antimicrobial Resistance
Surveillance 2000-2016. Available from: http://
narst.dmsc.moph.go.th/data/AMR%2020002016.pdf.[Last cited on 2017 May 2].
3. Werarak P, Waiwarawut J, Tharavichitkul P,
Pothirat C, Rungruanghiranya S, Geater SL,
et al. Acinetobacter baumannii nosocomial
pneumonia in tertiary care hospitals in Thailand.
J Med Assoc Thai. 2012;95(Suppl 2):S23-S33.
4. Inchai J, Liwsrisakun C, Theerakittikul T,
Chaiwarith R, Khositsakulchai W, Pothirat C.
Risk factors of multidrug-resistant, extensively
drug-resistant and pandrug-resistant Acinetobacter
baumannii ventilator-associated pneumonia in
a Medical Intensive Care Unit of university
hospital in Thailand. J Infect Chemother. 2015;
21(8):570-4.
5. Nakane T, Iyobe S, Sato K, Mitsuhashi S.
In vitro antibacterial activity of DU-6859a,
a new fluoroquinolone. Antimicrob Agents
Chemother.1995;39(12):2822-6.
6. Akasaka T, Tanaka M, Yamaguchi A, Sato K.
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas
9.
10.
11.
12.
13.
14.
aeruginosa isolated in 1998 and 1999: role of
target enzyme in mechanism of fluoroquinolone
resistance. Antimicrob Agents Chemother. 2001;
45(8):2263-8.
Tiengrim S, Phiboonbanakit D, Thunyaharn S,
Tantisiriwat W, Santiwatanakul S, Susaengrat W,
et al. Comparative in vitro activity of sitafloxacin
against bacteria isolated from Thai patients with
urinary tract infections and lower respiratory
tract infections. J Med Assoc Thai. 2012;95
(Suppl 2):S6e17.
Tiengrim S, Mootsikapun P, Wonglakorn L,
Changpradub D, Thunyaharn S, Tantisiriwat W,
et al. Comparative in vitro activity of sitafloxacin
against bacteria isolated from Thai patients with
urinary tract infections and lower respiratory
tract infections in 2016. J Med Assoc Thai.
2017;100(10):1061-72.
Thamlikitkul V, Tiengrim S. In vitro activity
of sitafloxacin against carbapenem-resistant
Acinetobacter baumannii. Int J Antimicrob
Agents. 2013;42(3):284-5.
Tantisiriwat W, Linasmita P. In vitro activity
of sitafloxacin and other antibiotics against
bacterial isolates from HRH Princess Maha
Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit
Hospital. J Med Assoc Thai. 2017;100(4):469-78.
Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L.
In vitro activities of sitafloxacin tested alone
and in combination with rifampin, colistin,
sulbactam, and tigecycline against extensively
drug-resistant Acinetobacter baumannii. Int J
Clin Exp Med. 2015;8(5):8135-40.
Huang YS, Wang JT, Sheng WH, Chuang YC,
Chang SC. Comparative in vitro activity of
sitafloxacin against bacteremic isolates of
carbapenem resistant Acinetobacter baumannii
complex. J Microbiol Immunol Infect. 2015;
48(5):545-51.
Clinical and Laboratory Standards institute.
Performance standards for antimicrobial
susceptibility testing: Twenty-sixth informational supplement. Wayne, PA: Clinical and
Laboratory Standards Institute; 2016.
Clinical and Laboratory Standards institute.
Performance standards for antimicrobial
Susceptibility testing: Twenty-Seventh
informational supplement. Wayne, PA: Clinical
and Laboratory Standards Institute; 2018.
41
T. Paiboonvong et al.
15. Magiorakos AP, Srinivasan A, Carey RB,
Carmeli Y, Falagas ME, Giske CG, et al.
Multidrug-resistant, extensively drugresistant
and pandrug-resistant bacteria: an international
expert proposal for interim standard definitions
for acquired resistance. Clin Microbiol Infect.
2012;18(3):268-81.
16. Hujer KM, Hujer AM, Endimiani A, Thomson
JM, Adams MD, Goglin M, et al. Rapid
determination of quinolone resistance in
Acinetobacter spp. J Clin Microbiol. 2009;47:
1436-42.
17. Yang H, Hu L, Liu Y, Ye Y, Li J. Detection of
the plasmid-mediated quinolone resistance
determinants in clinical isolates of Acinetobacter
baumannii in China. J Chemother. 2016;28(5):
443-5.
18. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI,
Syed A, Shields RK, et al. Colistin-resistant
Acinetobacter baumannii: beyond carbapenem
resistance. Clin Infect Dis. 2015;60(9):1295303.
19. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin
resistance of Acinetobacter baumannii: clinical
reports, mechanisms and antimicrobial strategies.
J Antimicrob Chemother. 2012;67(7):1607-15.
20. Jeannot K, Bolard A, Plesiat P. Resistance to
polymyxins in Gram-negative organisms. Int
J Antimicrob Agents. 2017;49(5):526-35.
42
Pharm Sci Asia 2020; 47 (1), 37-42
21. Olaitan AO, Morand S, Rolain JM. Mechanisms
of polymyxin resistance: acquired and intrinsic
resistance in bacteria. Front Microbiol. 2014;
5:643.
22. Ni W, Li Y, Guan J, Zhao J, Cui J, Wang R,
et al. Effects of efflux pump inhibitors on
colistin resistance in multidrug-resistant
Gram-negative bacteria. Antimicrob Agents
Chemother. 2016;60(5):3215-8.
23. Lertsrisatit Y, Santimaleeworagun W,
Thunyaharn S, Traipattanakul J. In vitro
activity of colistin mono- and combination
therapy against colistin-resistant Acinetobacter
baumannii, mechanism of resistance, and
clinical outcomes of patients infected with
colistin-resistant A. baumannii at a Thai
university hospital. Infect Drug Resist. 2017;
10:437-43.
24. Liu YY, Chandler CE, Leung LM, McElheny
CL, Mettus RT, Shanks RMQ, et al. Structural
modification of lipopolysaccharide conferred
by mcr-1 in gram-negative ESKAPE pathogens.
Antimicrob Agents Chemother. 2017;61(6):
e00580-17.
25. Al-Tawfiq JA, Laxminarayan R, Mendelson
M. How should we respond to the emergence
of plasmid-mediated colistin resistance in
humans and animals? Int J Infect Dis. 2017;
54:77-84.